David Alan Bennett

The paper analyzes RNA-seq data from Caribbean-Hispanic Alzheimer's patients and controls to identify ancestry-specific gene expression patterns associated with disease.

This paper uses multi-omic integration to identify molecular subtypes of aging in brain tissue, finding subtypes associated with cognitive decline.

The paper identifies cell-type and cell-subtype specific eQTLs in aging human cortex, revealing variant effects on gene expression and disease associations.

The paper shows that ELA-associated increased chromatin accessibility and expression of APOE4 in astrocytes contribute to higher AD risk in APOE4/4 carriers.

The paper identifies JMJD6 and other key drivers of Alzheimer's disease using predictive network analysis and validates their effects on amyloid-beta and tau pathology in human neurons.

The paper identifies key driver genes for microglial phagocytosis and repurposes riluzole to treat Alzheimer's Disease by enhancing SLC1A2 activity.

The paper investigates the association between mitochondrial genome abundance and Alzheimer's disease, finding lower abundance correlates with worse neuropathology and cognitive performance.

This study performs a meta-analysis of GWAS to identify new genetic loci associated with all-cause and vascular dementia, revealing shared and distinct risk factors.

This paper introduces BFGWAS_QUANT, a scalable Bayesian functional GWAS method that improves variant prioritization in Alzheimer's disease by integrating multivariate quantitative annotations.

The paper identifies regulatory mechanisms for 21 Alzheimer's disease risk loci in human microglia using transcriptome and chromatin accessibility profiling.

The paper develops PCBrainAge, an epigenetic age predictor for brain tissue, showing it better captures aging heterogeneity and links to Alzheimer's disease features than existing methods.

The paper uses proteomic profiling to classify cognitive impairment subtypes in human brain tissues, identifying distinct molecular patterns associated with different clinical outcomes.

This study identifies widespread metabolic dysregulation in Alzheimer's disease brain tissue, linking it to tau pathology and highlighting potential pathomechanisms.

The paper identifies NRN1 as a mediator of cognitive resilience to Alzheimer's disease through integrative proteomic analysis and functional validation in neurons.

The paper identifies somatostatin and intra-telencephalic neurons as significantly associated with Alzheimer's disease using bulk and single-nucleus transcriptomics across multiple datasets.

This study identifies disease-enriched microglial subsets and validates compounds that modulate their states using single-cell RNA sequencing and in vitro experiments.

This study analyzes somatic mosaicism in Alzheimer's Dementia using single-cell data, finding increased mutational burden in specific cell types and genes associated with disease processes.

The paper identifies structural variants in the human brain and their associations with molecular traits and neurodegenerative diseases.

The paper identifies cell-type-specific molecular changes in cerebrovascular cells across brain regions in Alzheimer's Disease, linking them to genetic variants and potential therapeutic targets.

This paper identifies PPP2CB and C4B as key genes linked to Alzheimer's disease through a systems biology approach, showing their association with tau pathology and complement pathway activation.

The paper analyzes proteomic data from Alzheimer's disease brains, revealing disease-related changes not seen at the RNA level and identifying potential therapeutic targets.

The paper identifies DNA methylation in the CLDN5 locus as associated with cognitive decline, independent of neuropathology, suggesting a role for the blood-brain barrier in cognitive trajectory.

The paper identifies differentially expressed mRNAs and microRNAs in human brain tissues associated with obesity and BMI using RNA sequencing from multiple cohorts.

The paper shows that insulin receptors in microvessels at the blood-brain barrier are defective in Alzheimer's disease, contributing to brain insulin resistance and cognitive impairment.

CEWAS improves gene detection from GWAS by modeling cascading epigenomic and transcriptomic effects, identifying disease-related genes and novel biological processes.

The paper identifies a co-expression network involving C4A, C4B, and HSPA2 linked to APOE ε2's protective effect against Alzheimer's disease, primarily associated with tau pathology.

The paper investigates the role of farnesyltransferase (FT) in Alzheimer's disease by analyzing human brain tissue and generating a mouse model with neuronal FT knockout, finding increased FT and farnesylation in AD and showing mitigation of pathology with FT suppression.

The paper uses single-cell transcriptomics to analyze the hippocampus and entorhinal cortex in Alzheimer's disease, identifying stage-specific molecular changes across cell types.

This study performs a meta-analysis of DNA methylation data from Alzheimer's disease patients to identify differentially methylated loci across brain regions and cortex.

This study characterizes human cerebrovascular cells in health and disease, identifying cell type-specific markers and revealing immune activation and BBB integrity loss in Huntington's disease.